ATE344022T1 - Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe - Google Patents

Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe

Info

Publication number: ATE344022T1
Authority: AT; Austria
Prior art keywords: peptide; proinsulin; delayed release; preparation containing; medicinal preparation
Prior art date: 2000-11-10

Application number

AT01980762T

Other languages

English (en)

Inventor

Detlef Mohr

Tim Seiffert

Original Assignee

Creative Peptides Sweden Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-10

Filing date

2001-11-08

Publication date

2006-11-15

2001-11-08 Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE344022T1 publication Critical patent/ATE344022T1/de

Links

VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 title abstract 4
108010075254 C-Peptide Proteins 0.000 title abstract 4
230000003111 delayed effect Effects 0.000 title abstract 4
238000009472 formulation Methods 0.000 abstract 3
239000000203 mixture Substances 0.000 abstract 3
206010012601 diabetes mellitus Diseases 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
239000011859 microparticle Substances 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Zoology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

AT01980762T 2000-11-10 2001-11-08 Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe ATE344022T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10055857A DE10055857A1 (de)	2000-11-10	2000-11-10	Neue pharmazeutische Depotformulierung

Publications (1)

Publication Number	Publication Date
ATE344022T1 true ATE344022T1 (de)	2006-11-15

Family

ID=7662892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01980762T ATE344022T1 (de)	2000-11-10	2001-11-08	Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe

Country Status (9)

Country	Link
US (1)	US20040053817A1 (de)
EP (1)	EP1337243B1 (de)
JP (1)	JP2004513143A (de)
AT (1)	ATE344022T1 (de)
AU (2)	AU2002212550B2 (de)
CA (1)	CA2428159A1 (de)
DE (2)	DE10055857A1 (de)
NZ (1)	NZ526162A (de)
WO (1)	WO2002038129A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0022342D0 (en) *	2000-09-12	2000-10-25	Creative Peptides Sweden Ab	Reduction of the electrocardiographic QT interval
AU2003205106A1 (en) *	2002-01-16	2003-09-02	Agency For Disease Diagnosis And Prevention	Pace-a microspheres for delivery of antigens
CN1745170A (zh)	2002-12-17	2006-03-08	米迪缪尼疫苗股份有限公司	生物活性材料的高压喷雾干燥
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
GB0323979D0 (en) *	2003-10-13	2003-11-19	Creative Peptides Sweden Ab	Therapeutic applications for c-peptide
CA2544678C (en)	2003-11-05	2013-12-31	Sunesis Pharmaceuticals, Inc.	Modulators of cellular adhesion
DK2444079T3 (en)	2005-05-17	2017-01-30	Sarcode Bioscience Inc	Compositions and Methods for the Treatment of Eye Diseases
GB0511269D0 (en) *	2005-06-02	2005-07-13	Creative Peptides Sweden Ab	Sustained release preparation of pro-insulin C-peptide
WO2007109605A2 (en) *	2006-03-20	2007-09-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions
ES2331342B1 (es) *	2006-05-22	2010-10-13	Consejo Superior Investg.Cientificas	Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
WO2008118387A2 (en) *	2007-03-23	2008-10-02	Wayne State University	Erythrocyte atp-release modulators
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2830024T3 (es)	2007-10-19	2021-06-02	Novartis Ag	Composiciones y métodos para el tratamiento del edema macular
WO2009139817A2 (en)	2008-04-15	2009-11-19	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011050175A1 (en)	2009-10-21	2011-04-28	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
KR20130115086A (ko)	2010-05-17	2013-10-21	세빅스 인코포레이티드	페길화된 c-펩티드
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
KR20200108932A (ko)	2012-07-25	2020-09-21	에스에이알코드 바이오사이언스 인코포레이티드	Lfa-1 저해제 및 그의 다형체
WO2014131024A2 (en)	2013-02-25	2014-08-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
JP6661531B2 (ja)	2013-10-10	2020-03-11	シナジーファーマシューティカルズインコーポレイテッド	オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
US10653744B2 (en)	2016-01-11	2020-05-19	Bausch Health Ireland Limited	Formulations and methods for treating ulcerative colitis
KR102371699B1 (ko) *	2019-12-17	2022-03-08	한국전자기술연구원	당뇨 추정 시스템 및 그 방법
CN116803378B (zh) *	2023-08-24	2023-11-17	北京福元医药股份有限公司	一种格列齐特缓释片剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4652548A (en) *	1981-08-27	1987-03-24	Eli Lilly And Company	Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
EP0625069B1 (de) *	1992-10-26	1998-12-30	Schwarz Pharma Ag	Verfahren zur herstellung von mikrokapseln
DE4406172C2 (de) *	1994-02-25	2003-10-02	Sanol Arznei Schwarz Gmbh	Polyester
US5942253A (en) *	1995-10-12	1999-08-24	Immunex Corporation	Prolonged release of GM-CSF
SE520392C2 (sv) *	1996-09-27	2003-07-01	Creative Peptides Sweden Ab C	Specifika peptider för behandling av diabetes mellitus
DE10041478A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
GB0022342D0 (en) *	2000-09-12	2000-10-25	Creative Peptides Sweden Ab	Reduction of the electrocardiographic QT interval
SE517421C2 (sv) *	2000-10-06	2002-06-04	Bioglan Ab	Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
DE10055742B4 (de) *	2000-11-10	2006-05-11	Schwarz Pharma Ag	Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
SE0201599D0 (sv) *	2002-03-21	2002-05-30	Skyepharma Ab	Microparticles

2000
- 2000-11-10 DE DE10055857A patent/DE10055857A1/de not_active Withdrawn
2001
- 2001-11-08 DE DE60124294T patent/DE60124294D1/de not_active Expired - Fee Related
- 2001-11-08 CA CA002428159A patent/CA2428159A1/en not_active Abandoned
- 2001-11-08 EP EP01980762A patent/EP1337243B1/de not_active Expired - Lifetime
- 2001-11-08 NZ NZ526162A patent/NZ526162A/en unknown
- 2001-11-08 AU AU2002212550A patent/AU2002212550B2/en not_active Ceased
- 2001-11-08 WO PCT/GB2001/004980 patent/WO2002038129A2/en not_active Ceased
- 2001-11-08 AU AU1255002A patent/AU1255002A/xx active Pending
- 2001-11-08 AT AT01980762T patent/ATE344022T1/de not_active IP Right Cessation
- 2001-11-08 JP JP2002540719A patent/JP2004513143A/ja active Pending
- 2001-11-08 US US10/416,173 patent/US20040053817A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2002038129A3 (en)	2003-02-13
EP1337243B1 (de)	2006-11-02
AU1255002A (en)	2002-05-21
DE10055857A1 (de)	2002-08-22
JP2004513143A (ja)	2004-04-30
EP1337243A2 (de)	2003-08-27
NZ526162A (en)	2005-01-28
WO2002038129A2 (en)	2002-05-16
US20040053817A1 (en)	2004-03-18
CA2428159A1 (en)	2002-05-16
DE60124294D1 (de)	2006-12-14
AU2002212550B2 (en)	2005-08-04

Legal Events

Date	Code	Title	Description
2007-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE344022T1 (de)	2006-11-15	Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
AU2003274681A1 (en)	2004-02-23	Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
BR0116169A (pt)	2003-12-23	Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BG66093B1 (bg)	2011-04-29	Състави с контролирано освобождаване, съдържащи нимесулид
DK0954314T3 (da)	2002-02-18	Doseringsformer til bedring af mandlig erektionsdefekt
MY124695A (en)	2006-06-30	Novel composition and use.
CY1105120T1 (el)	2010-03-03	Η αντιμετωπιση αναπνευστικων νοσων
MY127797A (en)	2006-12-29	3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
MX9204268A (es)	1994-03-31	Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
HRP20060147B1 (hr)	2014-02-14	Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
WO2002017918A3 (en)	2002-07-25	Sustained release formulations for growth hormone secretagogues
CY1110287T1 (el)	2015-01-14	Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
MX2007006212A (es)	2007-07-09	Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
ATE529097T1 (de)	2011-11-15	Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
BR0014142A (pt)	2002-07-02	Composição de vacina e método de empregar a mesma
BR0211198A (pt)	2004-08-10	Composições farmacêuticas e seu uso
ATE260650T1 (de)	2004-03-15	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
WO2002030467A3 (en)	2002-10-24	Pharmaceutical composition containing honey for the treatment of wounds
TW200505436A (en)	2005-02-16	Modified release pharmaceutical compositions and the processes for preparing them
EA200501223A1 (ru)	2006-04-28	Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
DE60028730D1 (de)	2006-07-27	Multipartikuläre bisoprolol formulierung
MXPA04003506A (es)	2004-07-23	Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn.
WO2003028624A3 (en)	2003-11-06	Levothyroxine compositions and methods
MY136546A (en)	2008-10-31	A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
AR012996A1 (es)	2000-11-22	Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.